CFM Pharma

CFM Pharma is a private, clinical-stage biotech leveraging its patented VANADIS® platform of organovanadium compounds to address significant unmet needs in acute trauma. Its lead candidate, VANADIS® BMOV, has completed Phase 1A safety studies for myocardial infarction and is Phase 1B-ready, with preclinical data showing up to 42% reduction in infarct size. The company is positioning itself for value inflection through clinical readouts and early-stage partnerships, targeting multi-billion dollar markets in cardiology, burn care, and acute kidney injury.

VANADIS® platform of proprietary organovanadium compounds and delivery technologies designed to protect and regenerate tissue by simultaneously dampening inflammation, oxidative stress, and apoptosis in acute trauma settings.

The acute trauma space is competitive, with numerous companies investigating anti-inflammatory, anti-apoptotic, and regenerative therapies. In myocardial infarction, CFM's compound would compete against existing reperfusion therapies and novel adjuvants in development. Its differentiation lies in its multi-pathway organovanadium platform and patented chemistry until 2042.